ライフサイエンスコーパス: cardiac myosin

1 y supported by rabbit skeletal and by bovine cardiac myosin.

2 hinery of the cardiac muscle, including beta-cardiac myosin.

3 utation, R453C, in the context of human beta-cardiac myosin.

4 therapeutic approaches to target human beta-cardiac myosin.

5 ossreactive with streptococcal M protein and cardiac myosin.

6 heterozygous for the mutation R403Q in beta-cardiac myosin.

7 arbil, a small-molecule, direct activator of cardiac myosin.

8 matogenic epitopes in the S2 region of human cardiac myosin.

9 CM-causing mutations are found in human beta-cardiac myosin.

10 cur within <200 mus of actin binding by beta-cardiac myosin.

11 athy mutations have been identified in human cardiac myosin.

12 yte and Ab responses after immunization with cardiac myosin.

13 tained a sequence identical in human and rat cardiac myosin.

14 d-type (cWT) or mutant (D778G or G741R) beta-cardiac myosin.

15 fy regions of disease enrichment within beta-cardiac myosin.

16 rg-712 in the converter domain of human beta-cardiac myosin.

17 sis for the kinetic and mechanical tuning of cardiac myosin.

18 osin, but this remains untested in mammalian cardiac myosins.

19 Cardiac myosin, a heart autoantigen, induced experimenta

20 structurally and immunologically similar to cardiac myosin, a well-known mediator of inflammatory he

21 Cardiac myosin activation may provide a new therapeutic

22 Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial funct

23 olecular motors.Omecamtiv mecarbil (OM) is a cardiac myosin activator that is currently in clinical t

24 We report the first study of the cardiac myosin activator, omecamtiv mecarbil, in patient

25 cts on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil.

26 othesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function

27 Agents that target contractility, such as cardiac myosin activators and novel adenosine triphospha

28 ugs with novel mechanisms of action, such as cardiac myosin activators, are under investigation for p

29 ight be improved by a new therapeutic class, cardiac myosin activators.

30 n rheumatic carditis target the S2 region of cardiac myosin and are similar among populations with rh

31 ted intracellular biomarker antigens such as cardiac myosin and brain tubulin, while targeting extrac

32 Immune responses against cardiac myosin and group A streptococcal M protein have

33 Our data suggest that cardiac myosin and its pathogenic T cell epitopes may li

34 treptococcal carbohydrate epitope GlcNAc and cardiac myosin and its peptides appear during progressio

35 in thymic epithelium conferred tolerance to cardiac myosin and prevented myocarditis, demonstrating

36 ry between streptococcal M protein and human cardiac myosin and represents some of the most well-defi

37 weaker than originally described for bovine cardiac myosin and thus the thermodynamic coupling betwe

38 atic carditis were cross-reactive with human cardiac myosin, and laminin, a valve protein.

39 urements of Ca(2+) sensitivity of human beta-cardiac myosin ATPase activity are consistent with the h

40 tracardiac CD45(+) leukocytes, elevated anti-cardiac myosin autoantibodies, and increased cardiac fib

41 Infection with T. cruzi induces cardiac myosin autoimmunity in susceptible humans and mi

42 To address how T. cruzi induces cardiac myosin autoimmunity, we investigated whether imm

43 t affect humoral immunity against T cruzi or cardiac myosin (autoimmunity) but did decrease delayed-t

44 16 was characterized as a cryptic epitope of cardiac myosin because it did not recall lymphocyte and

45 ntractility of the molecular motor, the beta-cardiac myosin (betaCM).

46 uced protein kinase (PK)A phosphorylation of cardiac myosin binding protein (cMyBP)-C may regulate cr

47 in essential and regulatory light chains and cardiac myosin binding protein (cMyBP)-C.

48 proteoform identification, endogenous human cardiac myosin binding protein C (140 kDa) was identifie

49 n kinase A-mediated (PKA) phosphorylation of cardiac myosin binding protein C (cMyBP-C) accelerates t

50 In the cardiac sarcomere, both cardiac myosin binding protein C (cMyBP-C) and troponin-

51 Cardiac myosin binding protein C (cMyBP-C) appears to mo

52 Cardiac myosin binding protein C (cMyBP-C) has a key reg

53 Cardiac myosin binding protein C (cMyBP-C) has three pho

54 scle contraction, and its accessory protein, cardiac myosin binding protein C (cMyBP-C), are the two

55 Cardiac myosin binding protein C (cMyBP-C), bound to the

56 The cardiac isoform [cardiac myosin binding protein C (cMyBP-C)] is essential

57 Decreased expression of cardiac myosin binding protein C (cMyBPC) as a result of

58 Decreased expression of cardiac myosin binding protein C (cMyBPC) in the heart h

59 Cardiac myosin binding protein C (cMyBPC) phosphorylatio

60 beta-adrenergic stimulation increases cardiac myosin binding protein C (MyBP-C) and troponin I

61 myopathy (FHC), individuals bearing a mutant cardiac myosin binding protein C (MyBP-C) gene usually h

62 ylated protein was identified as the 140-kDa cardiac myosin binding protein C (MyBPC).

63 d in several sarcomeric genes, including the cardiac myosin binding protein C (MYBPC3) gene.

64 ediated degradation of myosin heavy chain 6, cardiac myosin binding protein C, calcineurin (PPP3CB),

65 Homozygous cardiac myosin binding protein C-deficient (Mybpc(t/t))

66 ene analyses revealed 8 sequence variants in cardiac myosin binding protein-C (1 nonsense, 1 splice a

67 Phosphorylation of cardiac myosin binding protein-C (cMyBP-C) accelerates c

68 We investigated the influence of cardiac myosin binding protein-C (cMyBP-C) and its const

69 Although mutations in cardiac myosin binding protein-C (cMyBP-C) cause heart d

70 Although phosphorylation of cardiac myosin binding protein-C (cMyBP-C) has been reco

71 Cardiac myosin binding protein-C (cMyBP-C) is a member o

72 Cardiac myosin binding protein-C (cMyBP-C) is a thick fi

73 Cardiac myosin binding protein-C (cMyBP-C) is a thick-fi

74 We examined the effect of cardiac myosin binding protein-C (cMyBP-C) on contractil

75 Cardiac myosin binding protein-C (cMyBP-C) phosphorylati

76 The role of cardiac myosin binding protein-C (cMyBP-C) phosphorylati

77 microscopy, we examined the contribution of cardiac myosin binding protein-C (cMyBP-C) to thick-fila

78 Despite advances in the molecular biology of cardiac myosin binding protein-C (cMyBP-C), little is un

79 c proteins, most often MYBPC3, which encodes cardiac myosin binding protein-C (cMyBP-C).

80 ions in the gene encoding cardiac C-protein [cardiac myosin binding protein-C (cMyBP-C)] are one of t

81 cohort studies suggest that mutations in the cardiac myosin binding protein-C (MYBPC3) gene cause lat

82 ges to the thin filament: phosphorylation of cardiac myosin binding protein-C accelerates cross bridg

83 d in over 170 normal chromosomes; 1 variant (cardiac myosin binding protein-C Arg326Gln) also occurre

84 Mutations in the cardiac myosin binding protein-C gene (cMyBP-C) are amon

85 o a downregulation of S-glutathionylation of cardiac myosin binding protein-C in FTY720-treated Tm-E1

86 evidence suggesting that phosphorylation of cardiac myosin binding protein-C is a key regulator of t

87 mutations in thick filament proteins such as cardiac myosin binding protein-C or titin, cause familia

88 Cardiac myosin binding protein-C phosphorylation plays a

89 ted a transgenic (TG) mouse model expressing cardiac myosin binding protein-C with a non-phosphorylat

90 lly encoded] N'-terminal domains C0 to C7 of cardiac myosin binding protein-C) fragment and an insolu

91 recombinant] N'-terminal domains C0 to C7 of cardiac myosin binding protein-C)-sc returned pCa(50) an

92 Rather, mutations in cardiac myosin binding protein-C, troponin I, and alpha-

93 ilament proteins cardiac troponin (cTn)I and cardiac myosin-binding protein (cMyBP)-C.

94 us (Ser-23/24) of cardiac troponin I (cTnI), cardiac myosin-binding protein C (cMyBP-C) and titin.

95 Cardiac myosin-binding protein C (cMyBP-C) is a componen

96 Cardiac myosin-binding protein C (cMyBP-C) is a regulato

97 Cardiac myosin-binding protein C (cMyBP-C) is a sarcomer

98 Cardiac myosin-binding protein C (cMyBP-C) is a thick fi

99 Cardiac myosin-binding protein C (cMyBP-C) is a thick-fi

100 The N-terminal modules of cardiac myosin-binding protein C (cMyBP-C) play a regula

101 Cardiac myosin-binding protein C (cMyBP-C) plays a modul

102 Cardiac myosin-binding protein C (cMyBP-C) regulates act

103 e for a potential regulator of these motors, cardiac myosin-binding protein C (cMyBP-C), cause hypert

104 ns, to resolve the structure and dynamics of cardiac myosin-binding protein C (cMyBP-C), focusing on

105 Cardiac myosin-binding protein C (cMyC) is a cardiac-res

106 Mutations in cardiac myosin-binding protein C (MyBPC) gene have been

107 olamban at Ser16, phospholemman at Ser68 and cardiac myosin-binding protein C at Ser282, was unaltere

108 These results suggest that the 40-kDa cardiac myosin-binding protein C fragment, which is prod

109 on impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.

110 In this G+LVH- population, cardiac myosin-binding protein C mutation carriers had t

111 A stable 40-kDa fragment is produced from cardiac myosin-binding protein C when the heart is stres

112 eptide and disrupt the interaction of native cardiac myosin-binding protein C with the thin filament.

113 MYBPC3, encoding cMyBP-C (cardiac myosin-binding protein C), is the most frequentl

114 compared with cardiac troponins and cMyBP-C (cardiac myosin-binding protein C).

115 Cardiac myosin-binding protein C, a cardiac-specific myo

116 of cardiac myocyte proteins (alpha-actinin, cardiac myosin-binding protein C, and cardiac troponin I

117 th-old mice with gene targeted deficiency of cardiac myosin-binding protein-C (cMyBP-C(-/-), n=6) or

118 Phosphorylation of cardiac myosin-binding protein-C (cMyBP-C) by protein ki

119 Cardiac myosin-binding protein-C (cMyBP-C) is a thick fi

120 Cardiac myosin-binding protein-C (cMyBP-C) is a thick fi

121 Cardiac myosin-binding protein-C (cMyBP-C) is a thick-fi

122 Cardiac myosin-binding protein-C (cMyBP-C) is highly pho

123 ples, ADP sensitivity highly correlated with cardiac myosin-binding protein-C (cMyBP-C) protein level

124 M-domain is the major regulatory subunit of cardiac myosin-binding protein-C (cMyBP-C) that modulate

125 he unique myosin-binding motif (m-domain) of cardiac myosin-binding protein-C remains unclear.

126 ears have suggested that the interactions of cardiac myosin-binding protein-C with its binding partne

127 cMyBP-C (cardiac myosin-binding protein-C) is a critical regulato

128 ransient time-resolved FRET on a ventricular cardiac myosin biosensor.

129 Dynamics study of the motor domain of human cardiac myosin bound to OM, where the effects of the dru

130 eater unloaded shortening velocity than beta-cardiac myosin but a 2-fold lower average isometric forc

131 dy the mechanochemical properties of mutated cardiac myosin, but mouse hearts express alpha-MHC, wher

132 yopathy (DCM) mutation (F764L) in human beta-cardiac myosin by determining its motor properties in th

133 We previously demonstrated that cardiac myosin can use 2-deoxy-ATP (dATP) as an energy s

134 alysis of the motor domain of the human beta-cardiac myosin carrying the R453C mutation.

135 al relevance of autoantibodies (Abs) against cardiac myosin (CM) in clinical idiopathic dilated cardi

136 Miniature swine were immunized with cardiac myosin (CM) in Freund's adjuvant and received he

137 Because cardiac myosin (CM) is a dominant autoantigen in autoimm

138 sociated with an autoimmune process in which cardiac myosin (CM) is a major autoantigen.

139 e mechanisms by which autoantibodies against cardiac myosin (CM) may lead to heart dysfunction is unk

140 rafts triggers a CD4(+) Th1 cell response to cardiac myosin (CM), a major contractile protein of the

141 ssue-specific autoantigens such as vimentin, cardiac myosin (CM), collagen V (Col V), agrin, and angi

142 e to graft-expressed autoantigens, including cardiac myosin (CM), could participate.

143 We tested the impact of preexisting cardiac myosin (CM)-specific immunity on murine heart tr

144 response to a heart tissue-specific protein, cardiac myosin (CM).

145 al muscle myosin, smooth muscle myosin, beta-cardiac myosin (CMIIB), Dictyostelium myosin II (DdMII),

146 om no loop to one that is abnormally shaped, cardiac myosin (cmlc2) is present and contraction occurs

147 F-actin sliding on human fetal cardiac myosin-coated surfaces slowed significantly from

148 ivity (>=12-fold) for skeletal myosin versus cardiac myosin compared to BHC.

149 Cardiac myosin cycling kinetics, which directly control

150 erhaps more interesting, mice immunized with cardiac myosin developed T. cruzi-specific DTH and antib

151 g muscle motility, we demonstrate human beta-cardiac myosin-driven gliding of actin filaments on DNA

152 response, since C57BL/6 mice did not develop cardiac myosin DTH upon immunization with T. cruzi extra

153 proteolytic digestion of the C-loop in beta-cardiac myosin eliminates actin-activated myosin ATPase

154 ac myocyte performance by acute titration of cardiac myosin-embedded miR-208a.

155 Our report suggests that cardiac myosin epitopes in rheumatic carditis target the

156 ns, in which immunoglobulin G targeted human cardiac myosin epitopes in the S2 subfragment hinge regi

157 In human cardiac myosin, epitopes were demonstrated in the S2 and

158 ctin-binding region at the N terminus of the cardiac myosin essential light chain (ELC) remains elusi

159 In an in vitro motility assay, both mutant cardiac myosins exhibited a reduced ability to transloca

160 he border zone was associated with increased cardiac myosin expression and cardiac myocyte size (30 m

161 The structure of cardiac myosin filaments and the alterations caused by H

162 Cardiac myosin filaments consist of the molecular motor

163 reviously unstudied affinity of skeletal and cardiac myosin for phospholipid membranes.

164 he corresponding mutations in the human beta-cardiac myosin gene are associated with hypertrophic and

165 ta gene switching and implicates the role of cardiac myosin gene organization with their function.

166 mouse orthologs of two human enhancers near cardiac myosin genes.

167 ntamination by ~1:100 000 TF/myosin, whereas cardiac myosin had TF-like activity >10-fold higher.

168 It is well-established that rabbit alpha-cardiac myosin has a 2-fold greater unloaded shortening

169 Human beta-cardiac myosin has proved to be an excellent target for

170 A detailed kinetic analysis of cardiac myosin has shown that the drug accelerates phosp

171 tivity of the catalytic domain of human beta-cardiac myosin have not shown clear trends leading to hy

172 In this study we report that human cardiac myosin (HCM) acted as an endogenous ligand to di

173 , cardiac troponin I (2 missense), and alpha-cardiac myosin heavy chain (1 missense).

174 d by heterozygous missense mutations in beta-cardiac myosin heavy chain (beta-MHC).

175 tter prognosis than individuals bearing beta-cardiac myosin heavy chain (MHC) gene mutations.

176 ably transfected with cardiac-specific alpha-cardiac myosin heavy chain (MHC) promoter-driven enhance

177 diac alpha actin, atrial natriuretic factor, cardiac myosin heavy chain alpha, cardiac myosin heavy c

178 MNCs expressed the cardiac-specific antigens cardiac myosin heavy chain and cardiac troponin T, respe

179 nse mutations (S532P and F764L) in the alpha-cardiac myosin heavy chain and compared them with WT mic

180 for other loci, two muscle genes (Human beta-cardiac myosin heavy chain and myogenin) became localize

181 ic factor, cardiac myosin heavy chain alpha, cardiac myosin heavy chain beta, myosin light chain 1A,

182 action is disrupted when modeling human beta-cardiac myosin heavy chain cardiomyopathy mutations E497

183 sin binding protein-C, troponin I, and alpha-cardiac myosin heavy chain caused elderly-onset hypertro

184 Mutations in the beta-cardiac myosin heavy chain gene (beta-MyHC) are a major

185 Variation in the human beta-cardiac myosin heavy chain gene (MYH7) can lead to hyper

186 are caused by a premature stop codon in the cardiac myosin heavy chain gene myh6.

187 Cardiac myosin heavy chain isoform gene expression also

188 The two cardiac myosin heavy chain isoforms, alpha and beta, exh

189 banding of mice with or without an Arg403Gln cardiac myosin heavy chain mutation (alphaMHC403/+) prod

190 D2, or D3 under the regulation of the alpha cardiac myosin heavy chain promoter exhibited high rates

191 eat systolic heart failure via targeting the cardiac myosin heavy chain to increase myocardial contra

192 from cardiac myofilaments were identified on cardiac myosin heavy chain, actin, myosin light chains,

193 tion, circulating IgG autoantibodies against cardiac myosin heavy chain, and premature death due to h

194 Whereas defects in beta-cardiac myosin heavy chain, cardiac troponin T, and alph

195 the nucleus, whereas alpha-sarcomeric actin, cardiac myosin heavy chain, troponin I, and alpha-actini

196 notion, intracellular cardiac antigens, like cardiac myosin heavy chain-alpha, cardiac troponin-I, an

197 an Arg403Gln missense mutation in the alpha cardiac myosin heavy chain.

198 the adenosine triphosphatase activity of the cardiac myosin heavy chain.

199 chemical differences between the 2 mammalian cardiac myosin heavy chains (MHCs), alpha-MHC and beta-M

200 in, which shares sequence identity with beta-cardiac myosin-heavy chain, was used because of its stab

201 Using a human beta-cardiac myosin IHM quasi-atomic model, we defined intera

202 d by two bipolar arrays of the motor protein cardiac myosin II extending from the thick filament and

203 bstituted partially, and the CM-loop of beta-cardiac myosin II less well, for growth, capping of surf

204 ed Arg residue (whose mutation in human beta-cardiac myosin II results in familial hypertrophic cardi

205 This actin-binding loop is the site of a cardiac myosin-II mutation responsible for some forms of

206 ntal autoimmune myocarditis (EAM) induced by cardiac myosin immunization.

207 dominant epitope recognized by T cells from cardiac myosin immunized rats.

208 Omecamtiv mecarbil (OM)-a novel activator of cardiac myosin-improves left ventricular systolic functi

209 ced by immunizing rats (n = 18) with porcine cardiac myosin in complete Freund adjuvant.

210 ditis that is accompanied by autoimmunity to cardiac myosin in susceptible strains of mice.

211 dentified disease-specific epitopes of human cardiac myosin in the development of rheumatic carditis

212 ntracellular biomarkers of disease including cardiac myosin in the myocardium and tubulin, a protein

213 Here we determine the crystal structure of cardiac myosin in the pre-powerstroke state, the most re

214 primed position resulting in accumulation of cardiac myosin in the primed state prior to onset of car

215 electrostatic interactions between actin and cardiac myosin in vitro.

216 In our study, cardiac myosin induced valvulitis in the Lewis rat, and

217 Human and rat cardiac myosins induced severe myocarditis in the Lewis

218 Cardiac myosin-induced experimental autoimmune myocardit

219 Although cardiac myosin-induced myocarditis has been reported in

220 y and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hyp

221 dition of EMD 57033 to heat-inactivated beta-cardiac myosin is followed by refolding and reactivation

222 Mimicry between streptococcal M protein and cardiac myosin is important in the pathogenesis of rheum

223 ation of the regulatory light chain (RLC) of cardiac myosin is known to play a beneficial role in hea

224 Although cardiac myosin is known to produce myocarditis in suscep

225 Cardiac myosin is more radially displaced from the fiber

226 chanism of mavacamten-mediated inhibition of cardiac myosin is the decrease of phosphate release from

227 heterozygous for this mutation in the alpha-cardiac myosin isoform display typical familial hypertro

228 Thus, nature has adapted the function of cardiac myosin isoforms to optimize power output for hea

229 ffected only minor switches in the mammalian cardiac myosin isoforms.

230 The mammalian heart contains two cardiac myosin isoforms: beta-myosin heavy chain (MHC) i

231 irect evidence that immune responses against cardiac myosin lead to valvular heart disease and the in

232 autoimmune-susceptible SWXJ mice with whole cardiac myosin leads to T cell-mediated experimental aut

233 Because phosphorylation of cardiac myosin light chain 2 (MLC2v), bound to myosin at

234 c hypertrophy and failure, and a decrease in cardiac myosin light chain 2, an essential protein for c

235 her than the heart, we tested the use of the cardiac myosin light chain 2v (MLC-2v) promoter and the

236 single site to 0.45 mol of phosphate/mol by cardiac myosin light chain kinase (cMLCK) increases Ca(2

237 ly in vitro and in vivo, the precise role of cardiac myosin light chain kinase (cMLCK), the primary k

238 hosphorylated these recombinant species with cardiac myosin light chain kinase and zipper-interacting

239 hat neural crest cells invade and contribute cardiac myosin light chain2 (cmlc2)-positive cardiomyocy

240 ntly phosphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(

241 est that the depressed molecular function in cardiac myosin may initiate the events that cause the he

242 -dependent kinetics of individual human beta-cardiac myosin molecules interacting with an actin filam

243 muscle performance, yet its impact on human cardiac myosin motor function is unclear.

244 heavy meromyosin (sHMM) or full-length beta-cardiac myosin (MYH7).

245 tis (EAM) can be induced in the Lewis rat by cardiac myosin or its cryptic S2-16 peptide epitope (ami

246 n the T cell clones were stimulated by human cardiac myosin or other alpha-helical proteins, such as

247 These results suggest that immunization with cardiac myosin or T. cruzi antigen can induce specific,

248 skeletal heavy meromyosin (rsHMM) or porcine cardiac myosin (pcMyosin).

249 ing rat MBP69-89 peptide (RTL200), or to the cardiac myosin peptide CM-2 (RTL203).

250 itis (EAM), in which mice are immunized with cardiac myosin peptide, whereas IL-17A-deficient mice we

251 recruitment (100.9%, P<0.01), and increased cardiac myosin-positive area (39%, P<0.05) at 4, 7, and

252 vessels/mm2, P<0.01; SDF-1:MSC vs. MSC), and cardiac myosin-positive area (MSC: 49.5%; mSC:SDF-1: 162

253 Low-duty cycle skeletal and cardiac myosin present challenges for a single-molecule

254 osis factor-alpha (TNF-alpha) gene under the cardiac myosin promoter (TNF1.6 mice) develop dilated ca

255 loped computational models of the human beta-cardiac myosin protein before and after the myosin power

256 These transient kinetic studies on mouse cardiac myosins provide strong evidence that the functio

257 green fluorescent protein (GFP)-tagged human cardiac myosin regulatory light chain (HCRLC) was constr

258 22nd amino acid residue (E22K) in the human cardiac myosin regulatory light chain (RLC) gene causes

259 Understanding how cardiac myosin regulatory light chain (RLC) phosphorylat

260 Here, we studied the role of the cardiac myosin regulatory light chains (RLCs) in the cap

261 e in Lewis rats and have been linked to anti-cardiac myosin responses, we reacted myosin-sensitized l

262 We conclude that OM alters the energetics of cardiac myosin's mechanical cycle, causing the powerstro

263 e same exercise was repeated for human alpha-cardiac myosin S1 and rabbit fast skeletal muscle S1.

264 the decrease of phosphate release from beta-cardiac myosin-S1, a secondary mechanism decreases the n

265 biting the rate of phosphate release of beta-cardiac myosin-S1, but the molecular mechanism of action

266 Here, using human beta-cardiac myosin-S1, we combine published data from transi

267 urements using the expressed actins and beta-cardiac myosin showed that the mutation increased the K(

268 Expression of cWT beta-cardiac myosin significantly increased ttp and t0.5 and

269 r immunity to T. cruzi antigens could induce cardiac myosin-specific autoimmunity in the absence of l

270 sitosis in the heart accompanied by vigorous cardiac myosin-specific delayed-type hypersensitivity (D

271 adjuvant and found that these mice developed cardiac myosin-specific delayed-type hypersensitivity (D

272 Treatment also reduced cardiac myosin-specific DTH and antibody production.

273 2, IL-4, and TNF-alpha production as well as cardiac myosin-specific IgG1 and IgG2b production, where

274 It also led to increased cardiac myosin-specific IL-1 and TNF-alpha production.

275 We expressed and purified human beta-cardiac myosin subfragment 1 (M2beta-S1) containing a C-

276 We expressed and purified human beta-cardiac myosin subfragment 1 (M2beta-S1) containing the

277 ct and substituted it for the VELC of bovine cardiac myosin subfragment 1.

278 reports indicate that suspended skeletal and cardiac myosin, such as might be released during injury,

279 s indicate that purified skeletal muscle and cardiac myosins support the prothrombinase complex indir

280 ly administered, small-molecule modulator of cardiac myosin, targets underlying biomechanical abnorma

281 is a selective, small-molecule activator of cardiac myosin that is being developed as a potential tr

282 ) is a small molecule allosteric effector of cardiac myosin that is in clinical trials for treatment

283 discovered novel small-molecule modulator of cardiac myosin that targets the underlying sarcomere hyp

284 A structured surface loop on beta-cardiac myosin, the cardiac or C-loop, was recently demo

285 with some resulting from point mutations in cardiac myosin, the molecular motor of the heart.

286 t is linked to host immune responses against cardiac myosin, the most abundant protein in the heart.

287 In addition, pathogenic epitopes of human cardiac myosin, the S2 fragment peptides S2-16 and S2-28

288 with antibodies and T cell responses against cardiac myosin, there is no unifying hypothesis about ca

289 c native thin filaments and the S2 domain of cardiac myosin to show that site-specific phosphorylatio

290 ach for the study of mutations in human beta-cardiac myosin using the hypertrophic myopathy mutation

291 accelerates the actin-activated activity of cardiac myosin was able to rescue processivity of the D1

292 erentiation for 5-7 days, cWT or mutant beta-cardiac myosin was expressed at 25 % of total myosin in

293 ardiac myosin with those expressing cWT beta-cardiac myosin, we found that ttp and t0.5 were signific

294 synthetic peptides of the S2 region of human cardiac myosin, we identified an amino acid sequence, S2

295 We found that immune responses to cardiac myosin were similar in rheumatic carditis among

296 A/J mice, immunized with syngeneic cardiac myosin, were given 75 mg/L of captopril in their

297 en is a first-in-class targeted inhibitor of cardiac myosin, which has been shown to reduce LV outflo

298 the crystal structure of OM bound to bovine cardiac myosin, which shows that OM stabilizes the pre-p

299 exchanged endogenous RLC from native porcine cardiac myosin with recombinant human ventricular wild t

300 we compared myotubes expressing mutant beta-cardiac myosin with those expressing cWT beta-cardiac my